Home › Acute Myeloid Leukemia
Acute Myeloid Leukemia clinical trials recruiting in the U.S.
276 studies for Acute Myeloid Leukemia are recruiting participants at sites across the United States.
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
Cities with the most studies
- Houston, TX88 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Baldwin Park, CA41 studies
- Seattle, WA40 studies
- Durham, NC34 studies
- Columbus, OH34 studies
- Philadelphia, PA33 studies
- Atlanta, GA30 studies
- Tampa, FL30 studies
- Chicago, IL27 studies
- Los Angeles, CA25 studies
- Portland, OR24 studies
- Miami, FL24 studies
- St. Louis, MO23 studies
- Washington, DC22 studies
- Nashville, TN21 studies
- Birmingham, AL21 studies
- Edison, NJ20 studies
- Cleveland, OH20 studies
- Dallas, TX20 studies
- Buffalo, NY20 studies
- Winston-Salem, NC20 studies
- Cincinnati, OH20 studies
- Mountain View, CA19 studies
- Minneapolis, MN19 studies
- Baltimore, MD19 studies
- Queens, NY19 studies
- New Haven, CT18 studies
- Milwaukee, WI18 studies
- Charlotte, NC18 studies
- Rochester, NY18 studies
- Pittsburgh, PA18 studies
- Madison, WI17 studies
- Ann Arbor, MI17 studies
- Greenburgh, NY17 studies
- Salt Lake City, UT17 studies
- Aurora, CO16 studies
- Charlottesville, VA16 studies
- Oklahoma City, OK15 studies
By state
- Alabama21 studies
- Arizona23 studies
- Arkansas12 studies
- California79 studies
- Colorado22 studies
- Connecticut19 studies
- Delaware6 studies
- District of Columbia9 studies
- Florida56 studies
- Georgia38 studies
- Hawaii6 studies
- Idaho9 studies
- Illinois31 studies
- Indiana14 studies
- Iowa16 studies
- Kansas22 studies
- Kentucky14 studies
- Louisiana13 studies
- Maine10 studies
- Maryland31 studies
- Massachusetts44 studies
- Michigan24 studies
- Minnesota28 studies
- Mississippi7 studies
- Missouri24 studies
- Montana7 studies
- Nebraska10 studies
- Nevada4 studies
- New Hampshire9 studies
- New Jersey31 studies
- New Mexico9 studies
- New York72 studies
- North Carolina46 studies
- North Dakota7 studies
- Ohio56 studies
- Oklahoma15 studies
- Oregon26 studies
- Pennsylvania44 studies
- Rhode Island12 studies
- South Carolina16 studies
- South Dakota7 studies
- Tennessee31 studies
- Texas97 studies
- Utah17 studies
- Vermont7 studies
- Virginia22 studies
- Washington41 studies
- West Virginia6 studies
- Wisconsin26 studies
Recently updated studies
CD70.CAR for AML and Other CD70+ Leukemias
RecruitingPhase 1
Up to age 75 · All sexes · Updated Nov 13, 2026 · NCT06345027Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RecruitingPhase 1
Ages 65 and older · All sexes · Updated Nov 13, 2026 · NCT06552416Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07304011Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06317649Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07549464Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 1
Ages 21 and older · All sexes · Updated Nov 12, 2026 · NCT07737769Allogeneic iNKT Cell Therapy (agenT-797) After SCT
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07758218Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04774393Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Nov 12, 2026 · NCT02115295Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07007312Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT01311258ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07617363Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Nov 10, 2026 · NCT03589729The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
RecruitingPhase 1/2Healthy volunteers welcome
Ages 12 to 120 · All sexes · Updated Nov 10, 2026 · NCT05436418A Study of CRD3874-SI in People With Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07661095Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT04986657Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Nov 9, 2026 · NCT05554406Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Nov 9, 2026 · NCT06996119Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06930352CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT05672147Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04797767HPC Offered for PRESERVE Expansion
RecruitingObservational study
Ages 12 to 80 · All sexes · Updated Nov 6, 2026 · NCT07145411Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07223814Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Nov 6, 2026 · NCT07437950A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07751991From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.